{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T19:15:30Z","timestamp":1772997330232,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,8]]},"DOI":"10.7759\/cureus.104856","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T16:24:05Z","timestamp":1772987045000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World Outcomes of First-Line Pertuzumab, Trastuzumab, and Taxane in HER2-Positive Metastatic Breast Cancer in Costa Rica: A Multicenter Retrospective Study"],"prefix":"10.7759","author":[{"given":"Khanna","family":"Priyanka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis U","family":"Landaverde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","unstructured":"Ministerio de Salud de Costa Rica. An\u00e1lisis de incidencia y mortalidad por c\u00e1ncer. (2015). Accessed. November 2, 2025: https:\/\/www.ministeriodesalud.go.cr\/index.php\/biblioteca\/material-educativo\/material-publicado\/estadisticas-y-bases-d...."},{"key":"ref3","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdp261","article-title":"Third consensus on medical treatment of metastatic breast cancer","volume":"20","author":"Beslija S","year":"2009","unstructured":"Beslija S, Bonneterre J, Burstein HJ, et al.. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2009, 20:1771-1785.","journal-title":"Ann Oncol"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl S","year":"2017","unstructured":"Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017, 389:2415-2429.","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2711-y","article-title":"Prognosis of metastatic breast cancer subtypes: the hormone receptor\/HER2-positive subtype is associated with the most favorable outcome","volume":"141","author":"Lobbezoo DJ","year":"2013","unstructured":"Lobbezoo DJ, van Kampen RJ, Voogd AC, et al.. Prognosis of metastatic breast cancer subtypes: the hormone receptor\/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat. 2013, 141:507-14. 10.1007\/s10549-013-2711-y","journal-title":"Breast Cancer Res Treat"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159\/000346837","article-title":"HER2 dimerization inhibitor pertuzumab - mode of action and clinical data in breast cancer","volume":"8","author":"Harbeck N","year":"2013","unstructured":"Harbeck N, Beckmann MW, Rody A, et al.. HER2 dimerization inhibitor pertuzumab - mode of action and clinical data in breast cancer. Breast Care (Basel). 2013, 8:49-55. 10.1159\/000346837","journal-title":"Breast Care (Basel)"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.1080\/14712598.2017.1282944","article-title":"Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle","volume":"17","author":"Gerratana L","year":"2017","unstructured":"Gerratana L, Bonotto M, Bozza C, Ongaro E, Fanotto V, Pelizzari G, Puglisi F. Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle. Expert Opin Biol Ther. 2017, 17:365-374.","journal-title":"Expert Opin Biol Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.133","article-title":"Clinical trials: subgroup analyses in randomized trials--more rigour needed","volume":"12","author":"Altman DG","year":"2015","unstructured":"Altman DG. Clinical trials: subgroup analyses in randomized trials--more rigour needed. Nat Rev Clin Oncol. 2015, 12:506-7. 10.1038\/nrclinonc.2015.133","journal-title":"Nat Rev Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"Swain SM","year":"2013","unstructured":"Swain SM, Kim SB, Cort\u00e9s J, et al.. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013, 14:461-71. 10.1016\/S1470-2045(13)70130-X","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz061","article-title":"Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)","volume":"30","author":"Bachelot T","year":"2019","unstructured":"Bachelot T, Ciruelos E, Schneeweiss A, et al.. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Ann Oncol. 2019, 30:766-773.","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.024","article-title":"Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication","volume":"32","author":"Miles D","year":"2021","unstructured":"Miles D, Ciruelos E, Schneeweiss A, et al.. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann Oncol. 2021, 32:1245-55. 10.1016\/j.annonc.2021.06.024","journal-title":"Ann Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma S","year":"2012","unstructured":"Verma S, Miles D, Gianni L, et al.. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012, 367:1783-91. 10.1056\/NEJMoa1209124","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/471458-real-world-outcomes-of-first-line-pertuzumab-trastuzumab-and-taxane-in-her2-positive-metastatic-breast-cancer-in-costa-rica-a-multicenter-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T16:24:07Z","timestamp":1772987047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/471458-real-world-outcomes-of-first-line-pertuzumab-trastuzumab-and-taxane-in-her2-positive-metastatic-breast-cancer-in-costa-rica-a-multicenter-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,8]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.104856","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,8]]}}}